Hints and tips:
...in people with diabetes....
...ease pressure on health insurance and care systems....
...The UK health and social care department said more courses had been used, without offering its own data....
...But Amyris had also branched out into being an incubator for beauty start-ups including Rose Inc, Costa Brazil and JVN hair care, and it proved too huge a leap from developing molecules to developing brands...
...Don’t skip on the self-care. With his new venture, he has decided to cut back on wine and get a personal trainer, a performance coach and a health coach....
...The decision to withdraw from the scheme will not lower payments to the NHS from AbbVie, which makes one of the world’s best-selling drugs, Humira, and Eli Lilly, known for its diabetes drugs....
...Illumina was the fourth-largest spender on lobbying among biotech and pharma companies in 2022 at $9.4mn, behind only Pfizer, Roche and Amgen, which are much larger companies, according to an analysis by...
...“That [manufacturing] expertise will be important, especially with diabetes, which is more of a primary care market,” said Chen, adding that rivals Lilly and Novo Nordisk have experienced supply issues because...
...Job moves Former Roche boss Bill Anderson will become the next chief executive of Bayer. His predecessor Werner Baumann has faced pressure from activist investors including Jeff Ubben....
...Mr Schwan also told the FT that Roche was looking at point-of-care tests for the new coronavirus — rapid tests that could give results in a matter of minutes — though development is not yet at an advanced...
...Sami Inkinen, chief executive of Virta Health, a telemedicine clinic focused on type 2 diabetes, said simply giving people more information was not enough....
...“You can imagine, in the long run . . . someone experiences symptoms, they go to their primary care provider or urgent care and get a test....
...Pfizer and Roche are also developing antiviral pills. Trial results are expected before the end of the year. Additional reporting by Peter Wells in New York...
...“During the pandemic, there has been a huge increase in the burden of care work, due to closures of child care, elderly care and schools.”...
...The next battles over drug pricing in the US, the world’s largest drug market, are likely to focus on regular hikes in commonly used drugs such as those for diabetes, rather than costly treatments for rare...
...Remdesivir reminds some of Tamiflu, a drug co-developed by Gilead and Roche....
...Best from the journals Diabetes dangers Indian cities could be devastated by a jump in diabetes. Some 77m Indian adults currently have the disease, a number expected to almost double to 134m by 2045....
...Livongo, which uses technology tools such as coaching to help patients manage chronic ailments like diabetes, only went public in July last year at $28 a share....
...Mr Hudson also announced a simplification of Sanofi’s structure, with four core global business units to be reduced to three: speciality care covering immunology, rare diseases, rare blood disorders, neurology...
...Patients are often recommended these platforms by their employers, not their doctors, so they can cut out the traditional care providers....
...Verily products like Onduo, a joint venture with Sanofi to create a diabetes management platform, might move closer to Google Health....
...P&G controls more than a quarter of the global market for baby care products....
...A decade of growth has created “a much bigger pie” for all industry participants to share, says Mary Beth Roche, publisher of Macmillan Audio....
...It focuses on psychotropic, oncology and diabetes drugs....
...AstraZeneca Plc has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal...
International Edition